Literature DB >> 17077980

[Heart rate reduction as a therapeutic strategy: novel options].

U C Hoppe1.   

Abstract

Elevated heart rate is associated with increased cardiovascular mortality. Heart rate reduction optimises myocardial oxygen consumption and decreases angina pectoris symptoms. Thus, heart rate control is an important therapeutic strategy in coronary artery disease and, for example, chronic heart failure. The pacemaker current I(f) plays a central role in determining spontaneous activity of the sinus node. Ivabradine, a selective inhibitor of the I(f) channel, reduces heart rate without any effect on cardiac contractility and without lowering blood pressure. While beta-blockers remain the first choice for heart rate reduction, in cases of adverse effects ivabradine may be used to treat stable angina pectoris. Studies evaluating possible further uses, for example in heart failure or after acute myocardial infarction, are still warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077980     DOI: 10.1007/s00108-006-1749-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

Review 1.  Rest heart rate and life expectancy.

Authors:  H J Levine
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

2.  The epidemiology of resting heart rate in a national sample of men and women: associations with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors.

Authors:  R F Gillum
Journal:  Am Heart J       Date:  1988-07       Impact factor: 4.749

3.  How does adrenaline accelerate the heart?

Authors:  H F Brown; D DiFrancesco; S J Noble
Journal:  Nature       Date:  1979-07-19       Impact factor: 49.962

4.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.

Authors:  Ariel Diaz; Martial G Bourassa; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  Eur Heart J       Date:  2005-03-17       Impact factor: 29.983

5.  Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.

Authors:  Jean-Claude Tardif; Ian Ford; Michal Tendera; Martial G Bourassa; Kim Fox
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

6.  Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption.

Authors:  U E Heidland; B E Strauer
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

7.  Modulation of the hyperpolarization-activated inward current (If) by antiarrhythmic agents in isolated human atrial myocytes.

Authors:  U C Hoppe; D J Beuckelmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-12       Impact factor: 3.000

Review 8.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study.

Authors:  R J Goldberg; M Larson; D Levy
Journal:  Arch Intern Med       Date:  1996-03-11

10.  Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.

Authors:  Paul Mulder; Stephane Barbier; Abdeslam Chagraoui; Vincent Richard; Jean Paul Henry; Françoise Lallemand; Sylvanie Renet; Guy Lerebours; Florence Mahlberg-Gaudin; Christian Thuillez
Journal:  Circulation       Date:  2004-02-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.